The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first precision medicine combo for patients with BRCA2-mutated metasta | Akeega, a ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone (APP) for adults with deleterious or suspected deleterious BRCA2-mutated ...

The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...

On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

Scientists warn that the human Y chromosome has lost most of its genes over millions of years, and new research suggests ...

Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), enabling its use prior to chemotherapy for eligible ...